Skip to main content

Peer Review reports

From: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

Original Submission
2 Nov 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
16 Jan 2022 Reviewed Reviewer Report
12 Mar 2022 Author responded Author comments - Safa Najafi
Resubmission - Version 4
12 Mar 2022 Submitted Manuscript version 4
27 Mar 2022 Author responded Author comments - Safa Najafi
Resubmission - Version 5
27 Mar 2022 Submitted Manuscript version 5
15 Apr 2022 Reviewed Reviewer Report
1 May 2022 Author responded Author comments - Safa Najafi
Resubmission - Version 6
1 May 2022 Submitted Manuscript version 6
7 May 2022 Author responded Author comments - Safa Najafi
Resubmission - Version 7
7 May 2022 Submitted Manuscript version 7
6 Jun 2022 Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
14 Jul 2022 Editorially accepted
7 Sep 2022 Article published 10.1186/s12885-022-09895-5

You can find further information about peer review here.

Back to article page